Michael O. Clarke

8.4k total citations · 3 hit papers
17 papers, 3.0k citations indexed

About

Michael O. Clarke is a scholar working on Epidemiology, Infectious Diseases and Organic Chemistry. According to data from OpenAlex, Michael O. Clarke has authored 17 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 7 papers in Infectious Diseases and 6 papers in Organic Chemistry. Recurrent topics in Michael O. Clarke's work include Hepatitis C virus research (5 papers), Hepatitis B Virus Studies (4 papers) and Respiratory viral infections research (3 papers). Michael O. Clarke is often cited by papers focused on Hepatitis C virus research (5 papers), Hepatitis B Virus Studies (4 papers) and Respiratory viral infections research (3 papers). Michael O. Clarke collaborates with scholars based in United States and France. Michael O. Clarke's co-authors include Tomáš Cihlář, Robert Jordan, Joy Y. Feng, Mark R. Denison, Amy Sims, Ralph S. Baric, Timothy P. Sheahan, Richard L. Mackman, Dustin S. Siegel and Adrian S. Ray and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and PLoS ONE.

In The Last Decade

Michael O. Clarke

17 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

2020 1.2k citations Timothy P. Sheahan, Amy Sims et al. Nature Communications profile →
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

2018 1.0k citations Maria L. Agostini, Erica L. Andres et al. mBio profile →
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

2017 361 citations Michael K. Lo, Robert Jordan et al. Scientific Reports profile →

Peers

Countries citing papers authored by Michael O. Clarke

Since Specialization

Citations

This map shows the geographic impact of Michael O. Clarke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael O. Clarke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael O. Clarke more than expected).

Fields of papers citing papers by Michael O. Clarke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael O. Clarke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael O. Clarke. The network helps show where Michael O. Clarke may publish in the future.

Co-authorship network of co-authors of Michael O. Clarke

This figure shows the co-authorship network connecting the top 25 collaborators of Michael O. Clarke. A scholar is included among the top collaborators of Michael O. Clarke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael O. Clarke. Michael O. Clarke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV breakdown → 2020 ·Nature Communications ·Timothy P. Sheahan, Amy Sims, Sarah R. Leist, Alexandra Schäfer, John J. Won, Ariane J. Brown, Stephanie A. Montgomery, Alison Hogg, Darius Babusis, Michael O. Clarke, (unknown), Laura Bauer, Scott Sellers, Danielle Porter, Joy Y. Feng, Tomáš Cihlář, Robert Jordan, Mark R. Denison, Ralph S. Baric	1241
2	Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease breakdown → 2018 ·mBio ·Maria L. Agostini, Erica L. Andres, Amy Sims, Rachel L. Graham, Timothy P. Sheahan, Xiaotao Lu, Everett Clinton Smith, James Brett Case, Joy Y. Feng, Robert Jordan, Adrian S. Ray, Tomáš Cihlář, Dustin S. Siegel, Richard L. Mackman, Michael O. Clarke, Ralph S. Baric, Mark R. Denison	1026
3	Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs 2017 ·PLoS ONE ·Ona Barauskas, Weimei Xing, (unknown), Madeleine Willkom, (unknown), Michael O. Clarke, Gabriel Birkuš, Brian E. Schultz, Roman Sakowicz, (unknown), Joy Y. Feng	7
4	GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses breakdown → 2017 ·Scientific Reports ·Michael K. Lo, Robert Jordan, Aaron Arvey, Jawahar Sudhamsu, Punya Shrivastava-Ranjan, Anne L. Hotard, Mike Flint, Laura K. McMullan, Dustin S. Siegel, Michael O. Clarke, Richard L. Mackman, Hon C. Hui, Michel Perron, Adrian S. Ray, Tomáš Cihlář, Stuart T. Nichol, Christina F. Spiropoulou	361
5	Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Endonuclease activity and evaluation of inhibitors 2017 ·PLoS ONE ·Weimei Xing, Ona Barauskas, Thorsten Kirschberg, Anita Niedziela‐Majka, Michael O. Clarke, Gabriel Birkuš, (unknown), Xiaohong Liu, Brian E. Schultz, Roman Sakowicz, (unknown), Joy Y. Feng	4
6	Discovery of β-d-2′-deoxy-2′-α-fluoro-4′-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases 2015 ·Bioorganic & Medicinal Chemistry Letters ·Michael O. Clarke, Richard L. Mackman, Daniel Byun, Hon C. Hui, Ona Barauskas, Gabriel Birkuš, (unknown), Edward Doerffler, Joy Y. Feng, Kapil Karki, Gary Lee, Michel Perron, Dustin S. Siegel, S. Swaminathan, William Lee	20
7	A Small-Molecule Inhibitor of Hepatitis C Virus Infectivity 2013 ·Antimicrobial Agents and Chemotherapy ·(unknown), Maria Pokrovskii, (unknown), Philip Morganelli, Eda Canales, Michael O. Clarke, Scott E. Lazerwith, (unknown), Brian G. Reid, Kerim Babaoglu, Nikos Pagratis, Weidong Zhong, William E. Delaney, Matthew Paulson, Rudolf K. Beran	18
8	Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), T.C. Appleby, Thomas Butler, Ruby Cai, Xiaowu Chen, Aesop Cho, Michael O. Clarke, (unknown), William E. Delaney, Edward Doerffler, John O. Link, (unknown), Rowchanak Pakdaman, Hyung‐Jung Pyun, Qiaoyin Wu, Jie Xu, Choung U. Kim	26
9	Synthesis of 1-amino-2-vinylcyclopropane-1-phosphinates. Conversion of a phosphonate to phosphinates 2012 ·Tetrahedron Letters ·Hyung‐Jung Pyun, Michael O. Clarke, Aesop Cho, Anthony Casarez, (unknown), Maria Fardis, Richard Pastor, (unknown), Choung U. Kim	8
10	Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Anthony Casarez, Ruby Cai, Michael O. Clarke, Xiaowu Chen, Aesop Cho, William E. Delaney, Edward Doerffler, (unknown), Michael Mertzman, Rowchanak Pakdaman, Hyung‐Jung Pyun, (unknown), Qiaoyin Wu, Jie Xu, Choung U. Kim	28
11	Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease 2011 ·Bioorganic & Medicinal Chemistry Letters ·Michael O. Clarke, Daniel Byun, Xiaowu Chen, Edward Doerffler, Stephanie A. Leavitt, (unknown), Cheng Yong Yang, Choung U. Kim	9
12	Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease 2011 ·Bioorganic & Medicinal Chemistry Letters ·Michael O. Clarke, Xiaowu Chen, Aesop Cho, William E. Delaney, Edward Doerffler, Maria Fardis, (unknown), Michael Mertzman, Rowchanak Pakdaman, (unknown), (unknown), Cheng Yong Yang, (unknown), Choung U. Kim	18
13	Role of the A-Ring of Bryostatin Analogues in PKC Binding: Synthesis and Initial Biological Evaluation of New A-Ring-Modified Bryologs 2005 ·Organic Letters ·Paul A. Wender, Michael O. Clarke, Joshua C. Horan	17
14	Function Oriented Synthesis: The Design, Synthesis, PKC Binding and Translocation Activity of a New Bryostatin Analog 2004 ·Current Drug Discovery Technologies ·Paul A. Wender, Jeremy L. Baryza, Stacey E. Brenner, Michael O. Clarke, Madeleine Craske, Joshua C. Horan, Tobias Meyer	45
15	Inspirations from nature. New reactions, new therapeutic leads, and new drug delivery systems 2003 ·Pure and Applied Chemistry ·Paul A. Wender, Jeremy L. Baryza, Stacey E. Brenner, Michael O. Clarke, Gabriel G. Gamber, Joshua C. Horan, Theodore C. Jessop, Cindy Kan, Kanaka Pattabiraman, Travis J. Williams	37
16	The Practical Synthesis of a Novel and Highly Potent Analogue of Bryostatin 2002 ·Journal of the American Chemical Society ·Paul A. Wender, Jeremy L. Baryza, Chad Bennett, F. Christopher Bi, Stacey E. Brenner, Michael O. Clarke, Joshua C. Horan, Cindy Kan, Emmanuel Lacôte, Blaise Lippa, Peter G. Nell, (unknown)	130
17	Amino Acid-Derived Ligands for Transition Metals: Catalysis via a Minimalist Interpretation of a Metalloprotein 1997 ·Journal of the American Chemical Society ·B.D. Dangel, Michael O. Clarke, Jay Haley, Dalibor Sameš, Robin Polt	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact